NEWS ROOM
News2021-04-21T12:08:13+02:00
506, 2021

Patent application published covering novel technology to improve contact lens care solutions

Bubendorf, Switzerland, Saturday, June 5, 2021 - CIS Pharma’s new lens care patent application was published. The patent covers the latest developments in the field of contact lens care creating multi-purpose disinfecting solutions, MPDS, with an improved efficacy/safety profile. CIS Pharma’s innovation reduces the trade-off between efficacy and safety, inherent to MPDS that cover the complete contact lens care regimen [...]

3105, 2021

Preclinical development of lead antibody-radionuclide conjugate targeting L1CAM to treat cancer patients resistant to chemotherapy

Bubendorf, Switzerland, Monday, May 31, 2021 - CIS Pharma and the Paul Scherrer Institute of ETH were granted a two-year research program by Innosuisse to develop an antibody-radionuclide conjugate, ARC, at pre-clinical stage. The ARC is based on CIS Pharma’s polymer drug carriers to diagnose and treat L1CAM-positive forms of cancer. In addition, the research partners will investigate CIS Pharma’s [...]

2605, 2021

Patent granted in USA for CIS Pharma novel contact lens coating technology

Bubendorf, Switzerland, Wednesday, May 26, 2021 - CIS Pharma has developed a coating technology to improve the comfort of silicone hydrogel contact lenses. The technology is based upon a block-copolymer technology comprising a hydrophilic and a hydrophobic part. The co-polymer is used for a non-covalent, adhesive interaction with the silicone part of silicone-hydrogel contact lens to form a hydrophilic [...]

2005, 2021

Development of nanobody conjugate to cross blood brain barrier and treat brain tumors

Bubendorf, Switzerland, Thursday, May 20, 2021 - CIS Pharma has started the development of a nanobody against a novel tumor target. The target is a highly glycosylated transmembrane protein and plays a role in the adaptive immune system as a suppressor of T-cell activation & proliferation. It is a potential checkpoint inhibitor ligand. The antigen is homogeneously overexpressed in various [...]

1202, 2021

CIS Pharma demonstrates successful in-vivo biodistribution study for Oncology drug carrier

Bubendorf, Switzerland, Friday, February 12, 2021 - CIS Pharma has initiated the development of a humanized monoclonal antibody against the target L1CAM / CD 171. L1CAM is a surface protein that is overexpressed in ovarian, colorectal, lung and other forms of cancer, with a fast progression of the disease, a high spread of metastases and therefore poor prognosis. The antibody [...]

2701, 2021

Connected eye-drop dispenser development to achieve feasibility based on micro-dosing technology

Bubendorf, Switzerland, Wednesday, January 27, 2021 - CIS Pharma has achieved feasibility for its connected eye-drop dispenser by successfully evaluating micro-dosing technology for controlled and precise dispensing of an ophthalmic formulation treating dry eye disease. Uniformity of dispensed drops was achieved at a standard deviation of 1.2% at drop sizes as small as 10ul. CIS Pharma offers a platform of [...]

812, 2020

CIS Pharma demonstrates successful in-vivo biodistribution study for Oncology drug carrier

Bubendorf, Switzerland, Tuesday, December 8, 2020 - CIS Pharma successfully completed the biodistribution study with its polymer carrier technology applied to an antibody radionuclide conjugate (ARC). The conjugate was tested in a SKOvip mouse model, an aggressive form of ovarian cancer. The ARC tested comprised Trastuzumab as a model antibody to which two polymer carriers were conjugated that contained several [...]

612, 2020

CIS Pharma contact lens care solution shows enhanced biocompatibility, unsurpassed concentration of hyaluronic acid and a powerful disinfection complex

Bubendorf, Switzerland, Sunday, December 6, 2020 - CIS Pharma has successful up-scaled the production of its novel contact lens multipurpose and disinfection solution (MPDS) to an industrial setup. The contact lens care solution achieved excellent performance compared to products that are leading the markets. From an efficacy perspective, the antimicrobial performance against various bacteria & fungi was tested according to [...]

1510, 2020

CIS Pharma demonstrates in-vitro proof of concept for its ’s Oncology drug delivery technology

Bubendorf, Switzerland, Thursday, October 15, 2020 - CIS Pharma’s drug carrier technology has reached invitro proof of concept. A model antibody (Trastuzumab) was conjugated to two polymer carriers that were loaded with radioactive lucetium-177. The subsequent radioactive cell culture test (LINDMO method) showed that the affinity of CIS Pharma antibody radionuclide conjugate (ARC) to its target was similar compared to [...]

1405, 2020

CIS Pharma identifies lead polymer carrier for Oncology

Bubendorf, Switzerland, Thursday, May 14, 2020 - CIS Pharma’s polymer expert team has successfully reached the next milestone in its synthesis of the lead polymer carrier. Both analytical protocols as well as upscaling of the polymer technology has been established. “The quality and scale we have established is more than sufficient to enter into invivo studies” says Dr. Christophe Thommen, [...]

204, 2020

CIS Pharma Corona update

Bubendorf, Switzerland, Thursday, April 2, 2020 - CIS Pharma’s pipeline developments will experience some delay as a result of the Corona lock downs. Our Campus remains fully operational due to adequate space as well as due to efficient hygiene concepts. Unfortunately, some of our development partners had to face more stringent policies. We wish all of our partners to stay [...]

302, 2020

CIS Pharma attends EMSO sarcoma symposium in Milano

Milano, Italy, Monday February 3 to Wednesday February 5, 2020 - CIS Pharma attends the sarcoma symposium of the European Society for Medical Oncology, EMSO, in Milano. The event is a highly specialized meeting bringing together medical minds working on these tumor types. The symposium offered a good platform for CIS Pharma to discuss its oncology pipeline with known oncologists [...]

2301, 2020

CIS Pharma team attends the World Economic Forum in Davos

Davos, Switzerland, Thursday, January 23, 2020 – CIS Pharma attends the World Economic Forum in Davos, Switzerland. The main interest is to meet with its tracking technology partner modum.io and to attend the event provenance and transparency held at the Hotel Intercontinental in Davos. Tools against counterfeiting and instruments to create transparency in the value chain are two key areas [...]

801, 2020

CIS Pharma’s polymer-drug carriers successfully loaded with Lu-177 and In-111

Bubendorf, Switzerland, Wednesday, January 8, 2020 - In several laoding experiments Lutetium-177 and Indium-111 were loaded to CIS Pharma’s polymer-drug carriers, at high efficiency reates. Labeling density was close the level of metal chelators contained in the polymer-drug carrier, verifying the diversity that is offered by the polymer-drug carrier approach by loading different numbers of therapeutics to the antibody. Normally, [...]

1212, 2019

CIS Pharma PEEK implant program has reached the first milestone

Bubendorf, Switzerland, Thursday, December 12, 2019 - A new method for the modification of PEEK surfaces was established that significantly increases hydrophilicity of the material surface. The novel method is a scalable and convenient process and can be tailored to the desired physical properties of the PEEK surface. In preliminary cell culture experiments the modified PEEK surfaces have shown positive [...]

912, 2019

CIS Pharma’s polymer-drug carriers to load radioisotopes show excellent performance in a multiparameter toxicity study

Bubendorf, Switzerland, Monday, December 9, 2019 - CIS Pharm has tested several of its new polymer-drug carriers to conjugate radionuclides in a multiparameter cytotoxicity study at Cyprotex, a CRO based out of the UK and known for its expertise in ADME-tox. No matter what the loading capacity for radionuclides, the polymer-drug carriers show no toxicity effects in cell culture models [...]

612, 2019

CIS Pharma Christmas event in Arlesheim on ice

Arlesheim, Switzerland, Friday, December 6, 2019 - The team of CIS Pharma sets out on sheer ice, armed with stone and broom. After a short introduction, we are ready to play Curling, the traditional sport from Scotland. Gradually, we know how to handle the 20 kg stones and the competition starts: In two teams we take turns sliding heavy, polished granite [...]

2211, 2019

CIS Pharma team attends Asia-Pacific vitreo-retina society congress

Shanghai, China, Friday, November 22, 2019 – CIS Pharma is attending the Asia-Pacific vitreo-retina society congress in Shanghai to meet potential partners for its technologies in eye care during the three-day conference in Shanghai China. The Congress is an established, first rate platform in the Asia-Pacific region for scientific exchange, research and discovery in the field of vitreo-retinal diseases and [...]

111, 2019

CIS Pharma successfully conjugated a model antibody to its polymer-drug carrier comprising radioisotopes

Bubendorf, Switzerland, Friday, November 1, 2019 - Within the scope of the proof-of-concept study at the Paul Scherer Institute, a number of polymer-drug carriers enabling the conjugation of different amounts of radioisotopes, were successfully conjugated to model antibody trastuzumab. The site-directed conjugation of the antibody with different polymer-drug carriers was nearly quantitatively. The required excess of polymer as well as [...]

2910, 2019

CIS Pharma and the University of Appplied Sciences present their bio-membrane project at the Nano-Tech Event in Baden

Baden, Switzerland, Tuesday, October 29, 2019 - CIS Pharma and the University of Applied Sciences, FHNW Muttenz, are giving a talk at the Nano-Tech Apèro of the Swiss Nanoscience Institute, SNI. During the annual event scientist from academia and the industry gather to exchange their latest learinings on the field of nanoscience. CIS Pharma presents its recent achievements in project [...]

2810, 2019

Actinium announces positive interim results of antibody-radionuclide conjugate Iomab-B pivotal trial

New York, USA, Monday, October 28, 2019 - Actinium Pharmaceuticals Inc. announced key interim findings from the pivotal Phase 3 SIERRA trial of Iomab-B, an antibody-radionuclide conjugate, including feasibility and safety data. The Study of Iomab-B in Elderly Relapse/Refractory Acute Myeloid Leukemia, SIERRA, is a 150-patient, Phase 3 pivotal trial that is studying Iomab-B, Iodine-131 conjgated to apamistamab, compared to [...]

509, 2019

CIS Pharma initiates a proof of concept program for its novel polymer-drug carriers tailored to radioisotopes

Bubendorf, Switzerland, Wednesday, September 5, 2019 - CIS Pharma has signed a research agreement with the Paul Scherer Institute, Switzerland. The program comprises an invitro and invivo program for the conjugation of novel polymer-drug carriers to a model antibody by site-directed conjugation strategy and the labeling with suitable radioisotopes for diagnostic and therapeutic use. The antibody-radionuclide conjugates based on CIS [...]

1907, 2019

CIS Pharma summer event at the Rhine Falls

Schaffhausen, Switzerland, Friday, July 19,  2019 - During our Summer Event we take a boat ride along the banks of the Rhine Falls in Schaffhausen. The spectacular falls offers a refreshing spray of water. Next stop is Stein am Rhein, a beautiful town known for its medieval half-timbered houses. By boat we get to Steckborn, a small town on the [...]

1006, 2019

FDA approves novel antibody-drug conjugate Polivy

Maryland, USA, Monday, June 10, 2019 - The U.S. Food and Drug Administration granted accelerated approval to Polivy - polatuzumab vedotin-piiq, Roche - in combination with the chemotherapy bendamustine and a rituximab product to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies. Polivy is a novel antibody-drug conjugate, [...]

2504, 2019

CIS Pharma initiates a new R&D program in the field of PEEK implants

Bubendorf, Switzerland, Thursday, April 25, 2019 - In a new research program the surface of PEEK medical implants will modified to enhance osteointegration and soft-tissue compatibility. The modification is targeting the use of PEEK at the at the hard-to-soft-tissue interface such as in dental applications. PEEK or Poly-ether-ether-ketone has been used as an implant material in craniofacial application for several years. [...]

Nach oben